"We are discussing with public health leaders around the world to decide what we think is the best strategy for the potential booster for the fall of 2022. We believe it will contain omicron," Bancel said.
The Omicron-specific booster shot will soon enter clinical trials as Moderna prepares to supply as many as 2-3 billion booster doses this year alone, according to the report.
The United Kingdom, South Korea, Switzerland have already placed orders for Moderna boosters worth $18.5 billion, the report said.
Last week, the US Food and Drug Administration shortened the interval between receiving the initial COVID-19 vaccine doses produced by Moderna and getting a booster shot from six months to five in American adults 18 and older.
Omicron remains the predominant variant of the coronavirus in the United States and accounts for 95.4% of new infections, according to data compiled by the Centres for Disease Control and Prevention during the week ending 1 January.